M&A deal growth, the AI revolution, and the market surge of GLP-1 weight-loss medicines represent a trio of hot trends propelling the biopharmaceutical industry.
Tag Archive for: semaglutide
There are several other drug developers aiming to join the weight loss drug bandwagon. The following is a list of publicly listed companies targeting the next big blockbuster opportunity.
Anti-obesity drugs have revolutionized the market in the last few years, and have been identified as the emerging industry trend likely to have the greatest impact on the biopharmaceutical industry in the next 12 months, according to GlobalData.
Full data from the FLOW study show that Novo Nordisk’s top-selling GLP-1 receptor agonist semaglutide can significantly reduce the risk of death by 20% in diabetes patients with chronic kidney disease.
Presented at this week’s European Congress on Obesity, the two studies also demonstrate that Novo Nordisk’s Wegovy (semaglutide) provides cardiovascular benefits irrespective of starting weight and the amount of weight lost.
With GLP-1 agonists slated to become the best-selling drugs in 2024, the biopharma industry is already pivoting to explore treatments that preserve muscle mass as patients shed pounds.
Sen. Bernie Sanders (I-Vt.) on Wednesday launched an investigation into the exorbitant prices of Novo Nordisk’s Ozempic and Wegovy blockbusters, and has asked the Danish drugmaker to justify their price tags.
The European Medicines Agency announced on Friday that it has found no causal association between GLP-1 receptor agonists—a popular class of weight-loss treatments that include Novo Nordisk’s Wegovy (semaglutide)—and the risks of suicidal thoughts and actions.
GLP-1 receptor agonists—a popular drug class that includes Novo Nordisk’s Ozempic (semaglutide) and Victoza (liraglutide)—do not appear to increase the risk of thyroid cancer, according to a new study published Wednesday in The BMJ.
The European Medicines Agency is set to review several diabetes and weight-loss treatments this week in connection with potential increased risk of suicidal ideation and self-harm, according to a draft agenda document of the agency’s Pharmacovigilance Risk Assessment Committee.